Expanding the clinical and immunological phenotypes of PAX1-deficient SCID and CID patients

扩展PAX1缺陷型SCID和CID患者的临床和免疫学表型

阅读:3
作者:Nalan Yakici,Alexandra Y Kreins,Mehmet Cihangir Catak,Royala Babayeva,Baran Erman,Heather Kenney,Hatice Eke Gungor,Pablo A Cea,Tomoki Kawai,Marita Bosticardo,Ottavia Maria Delmonte,Stuart Adams,Yu-Tong Fan,Francesca Pala,Ayberk Turkyilmaz,Evey Howley,Austen Worth,Hakan Kot,Asena Pinar Sefer,Altan Kara,Alper Bulutoglu,Sevgi Bilgic-Eltan,Melek Yorgun Altunbas,Feyza Bayram Catak,Ibrahim Serhat Karakus,Emrah Karatay,Sidem Didar Tekeoglu,Metin Eser,Davut Albayrak,Senol Citli,Ayca Kiykim,Elif Karakoc-Aydiner,Ahmet Ozen,Sujal Ghosh,Holger Gohlke,Fazil Orhan,Luigi D Notarangelo,E Graham Davies,Safa Baris

Abstract

Paired box 1 (PAX1) deficiency has been reported in a small number of patients diagnosed with otofaciocervical syndrome type 2 (OFCS2). We described six new patients who demonstrated variable clinical penetrance. Reduced transcriptional activity of pathogenic variants confirmed partial or complete PAX1 deficiency. Thymic aplasia and hypoplasia were associated with impaired T cell immunity. Corrective treatment was required in 4/6 patients. Hematopoietic stem cell transplantation resulted in poor immune reconstitution with absent naïve T cells, contrasting with the superior recovery of T cell immunity after thymus transplantation. Normal ex vivo differentiation of PAX1-deficient CD34+ cells into mature T cells demonstrated the absence of a hematopoietic cell-intrinsic defect. New overlapping features with DiGeorge syndrome included primary hypoparathyroidism (n = 5) and congenital heart defects (n = 2), in line with PAX1 expression during early embryogenesis. Our results highlight new features of PAX1 deficiency, which are relevant to improving early diagnosis and identifying patients requiring corrective treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。